145375-43-5

145375-43-5 structure

Name: Mitiglinide
Chemical Name: [2(S)-cis]-Octahydro-γ-oxo-α-(phenylmethyl)-2H-isoindole-2-butanoic acid
CAS Number: 145375-43-5
Molecular Formula: C₁₉H₂₅NO₃
Molecular Weight: 315.41
Catalog: API Hormone and endocrine-regulating drugs Pancreatic hormones and other blood sugar regulating drugs
Create Date: 2018-06-02 08:00:00
Modify Date: 2024-01-03 20:09:27
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

Name	[2(S)-cis]-Octahydro-γ-oxo-α-(phenylmethyl)-2H-isoindole-2-butanoic acid
Synonyms	Mitiglinide Unii-D86I0xlb13 (-)-(2S,3a,7a-cis)-α-Benzylhexahydro-γ-oxo-2-isoindolinebutyric acid (2S)-2-Benzyl-4-((3a,7a-cis)-octahydro-2H-isoindol-2-yl)-4-oxobutanoic Acid (-)-(2S,3a,7a-cis)-a-Benzylhexahydro-g-oxo-2-isoindolinebutyric Acid (2S)-2-Benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxobutanoic acid 2H-Isoindole-2-butanoic acid, octahydro-γ-oxo-α-(phenylmethyl)-, (αS,3aR,7aS)-

Description	Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].
Related Catalog	Research Areas >> Metabolic Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> Potassium Channel
Target	KATP channel[1]
In Vitro	Mitiglinide inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 of 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells[1].
In Vivo	Mitiglinide (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load[2]. Animal Model: Pregnant Wistar rats (12 weeks)[2] Dosage: 0.3 mg/kg, 1 mg/kg, 3 mg/kg Administration: Oral administration Result: Dose-dependently suppressed AUCglucose levels.
References	[1]. Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25. [2]. Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29(5-6):423-7.

Density	1.2±0.1 g/cm3
Boiling Point	519.6±43.0 °C at 760 mmHg
Molecular Formula	C₁₉H₂₅NO₃
Molecular Weight	315.41
Flash Point	268.0±28.2 °C
Exact Mass	315.183441
PSA	57.61000
LogP	4.73
Vapour Pressure	0.0±1.4 mmHg at 25°C
Index of Refraction	1.567

HS Code	2942000000

Precursor 5
787635-24-9 1470-99-1 1141896-00-5 125702-11-6
140903-48-6
DownStream 0

HS Code	2942000000

145375-43-5	145324-16-9
145525-41-3	145375-44-6
207844-01-7	1266354-02-2
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4
849349-65-1	127437-46-1